Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EPRO for Adjuvant Therapy of Colorectal Adenocarcinoma

ABSTRACT: It is a multi-centric randomized controlled trial. The goal of this study is to observe the improvement of QoL using ePRO to manage patients with colorectal cancer who received Oxaliplatin-based adjuvant chemotherapy.The prognosis will also be studied.

DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2314733 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

microRNA levels in patients receiving CRT

Project description:This is a discovery cohort of six patients who received CRT with significant improvement in ejection fraction (EF), and six who received CRT but did not experience improvement. All patients are male, with left bundle branch block and do not have coronary disease (non-ischemic myopathy). Patients are matched for age and ejection fraction (EF)

2016-01-31 | GSE53821 | GEO

Novel adjuvant therapies for pancreatic adenocarcinoma.

Project description: Not available

| S-EPMC4502164 | biostudies-literature

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Project description:The goal of this clinical research study is to learn if panitumumab can help to control advanced cancer of the small bowel or ampulla of Vater. The safety of this drug will also be studied.

| 2095137 | ecrin-mdr-crc

Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study

Project description:The goal of this observational study is to learn about in small bowel adenocarcinoma patients. The main question it aims to answer is the association between tumor size and prognosis in patients with small bowel adenocarcinoma. Participants will be compared for the relationship between tumor size and prognosis.

| 109722 | ecrin-mdr-crc

Project description:GOAL sputum microbiome

| PRJNA464367 | ENA

Efficacy of orally administered LEM extract on host QOL and side effect in colorectal cancer patients treated with adjuvant chemotherapy (XELOX).

Project description:Interventions: Orally administered LEM of 1,800mg/day for 6 months during adjuvant chemotherapy (XELOX) Orally administered placebo for 6 months during adjuvant chemotherapy (XELOX) Primary outcome(s): Improvement of QOL with LEM in patients undergoing adjuvant chemotherapy Study Design: Parallel Randomized

| 2642437 | ecrin-mdr-crc

Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus.

Project description: Not available

| S-EPMC3415720 | biostudies-literature

Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Project description: Not available

| S-EPMC4991774 | biostudies-literature

Integrated Analysis of Genome-Wide DNA Copy Number and Gene Expression with Patient Outcomes in Esophageal Adenocarcinoma [Copy Number]

Project description:Esophageal adenocarcinoma (EAC) is now the most common esophageal malignancy in the United States with >15,000 new cases per year. Prognosis for patients with EAC is poor due to both late diagnosis and early metastasis to lymph nodes. The goal of this study was to perform an integrated analysis of genome-wide DNA copy number changes, gene expression and patient clinical data in order to identify events and genes associated with clinical endpoints or that may play a key role in EAC development and therefore provide potential therapeutic targets. Specifically, we report on a series of 116 EAC specimens studied using Affymetrix SNP 6.0 and U133 Plus 2 GeneChip arrays plus additional cohorts of 73 and 114 EAC patients whose tumors were analyzed using Affymetrix StyI 250K arrays and fluorescence in-situ hybridization (FISH) respectively. Integration of this genomic data with clinical information and outcomes enabled identification of copy number changes and coordinate gene expression events that are associated with patient prognosis, that validate known or suspected oncogenes and tumor suppressor genes and that also facilitate identification of novel, putative driver genes in large regions of copy number gain and loss. These findings add to our understanding of the basic biology of EAC and provide a guide for development of novel prognostic tools and therapies.

2016-11-01 | GSE72660 | GEO

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Project description:The goal of this phase 1/2a sporozoite challenge trial (NCT01883609) was to evaluate novel malaria vaccination regimens of the GSK pre-erythrocytic RTS,S/AS01B vaccine alone and concomitantly same-site administered with the viral vectors ChAd63 & MVA encoding the liver stage antigen construct ME-TRAP. Four vaccine groups were studied and received three vaccinations at a monthly interval. All subjects then underwent controlled human malaria infection (CHMI) 11 weeks after first vaccine administration.

2020-09-01 | GSE103862 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data